Why Is Johnson & Johnson (JNJ) Up 7.2% Since Last Earnings Report?

Johnson & Johnson reported robust Q2 2025 results, with adjusted earnings of $2.77 per share and sales of $23.74 billion, both exceeding consensus estimates. The strong performance was driven by growth in its Innovative Medicines segment, bolstered by key products and new drug launches, and its MedTech segment, benefiting from recent acquisitions, despite a significant revenue impact from Stelara's loss of exclusivity. Consequently, J&J raised its full-year 2025 sales guidance to $93.2-$93.4 billion and adjusted EPS guidance to $10.80-$10.90, signaling confidence in sustained operational momentum, particularly in the second half.

Analysis

Johnson & Johnson demonstrated significant operational strength in its Q2 2025 earnings report, delivering beats on both revenue and earnings per share. Sales reached $23.74 billion against a $22.80 billion estimate, and adjusted EPS came in at $2.77, surpassing the $2.66 consensus. This performance is particularly robust considering the substantial headwind from the Stelara loss of exclusivity (LOE), which saw the drug's sales plummet 42.7% and negatively impacted total revenue growth by 710 basis points. The company's ability to absorb this impact was driven by strong execution in its diversified portfolio. The Innovative Medicines segment grew sales by 4.9%, fueled by impressive growth in key oncology and immunology products such as Darzalex (+23.0%), Erleada (+23.4%), and Tremfya (+31.0%), alongside significant contributions from newer drugs like Carvykti and Tecvayli. The MedTech segment also outperformed with 7.3% sales growth, bolstered by recent acquisitions in the cardiovascular space which drove a 23.5% increase in that division's sales. Reflecting this underlying strength, management raised its full-year 2025 guidance, lifting the sales forecast to a range of $93.2-$93.4 billion and the adjusted EPS outlook to $10.80-$10.90. This upward revision, supported by operational momentum, currency tailwinds, and lower tariff estimates, signals confidence in an accelerating growth profile for the second half of the year, despite ongoing challenges like biosimilar competition and headwinds in China's MedTech market.

Key Decisions for Investors

• Investors should focus on the sales velocity of key growth assets like Darzalex, Tremfya, and Carvykti, as their ability to consistently outperform is critical to validating the thesis that J&J can successfully navigate the Stelara patent cliff.
• The MedTech segment's performance, particularly the continued integration and growth from the Abiomed and Shockwave acquisitions, should be monitored as a primary driver of diversification and future top-line expansion, while also tracking any commentary on the persistent headwinds from China's VBP program.
• Given the stock's 7.2% outperformance since the report and the mixed signals of a Zacks #3 (Hold) rating versus strong momentum and upward estimate revisions, a disciplined approach to valuation is warranted before initiating or expanding positions, as much of the positive news may already be priced in for the near term.